Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing promising effects in addressing obesity and type non-insulin-dependent diabetes. Animal data suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/